Percentage of Participants Reporting Pre-Specified Local Reactions During the 4-day period after each dose [clinicaltrials_resource:18d613e519c12e0676db59c0edec4115]
Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (>7.0 cm). Participants may be represented in more than 1 category.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Percentage of Participants Reporting Pre-Specified Local Reactions During the 4-day period after each dose [clinicaltrials_resource:18d613e519c12e0676db59c0edec4115]
Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (>7.0 cm). Participants may be represented in more than 1 category.
Bio2RDF identifier
18d613e519c12e0676db59c0edec4115
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:18d613e519c12e0676db59c0edec4115
measure [clinicaltrials_vocabulary:measure]
Percentage of Participants Reporting Pre-Specified Local Reactions
time frame [clinicaltrials_vocabulary:time-frame]
During the 4-day period after each dose
description
Local reactions were collected ...... ented in more than 1 category.
identifier
clinicaltrials_resource:18d613e519c12e0676db59c0edec4115
title
Percentage of Participants Rep ...... e 4-day period after each dose
@en
type
label
Percentage of Participants Rep ...... 613e519c12e0676db59c0edec4115]
@en